Fairman Group
JAZZ icon

Fairman Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Fairman Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-11
Closed -$2.65K – 339
2026
Q2 		$2.65K Hold
11
– – ﹤0.01% 269
2026
Q1 		$2.08K Hold
11
– – ﹤0.01% 281
2025
Q4 		$1.87K Buy
+11
New +$1.69K ﹤0.01% 290

Other funds holding JAZZ

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Polaris Capital Management
Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Argent Capital Management
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.9B AUM 30.31% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Fairman Group's JAZZ Position: Q3 2026 in Review

Fairman Group sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2026, closing a stake of 11 shares — an estimated $2.65K sold.

Fairman Group first reported a position in JAZZ in Q4 2025 and held it in 3 quarters. The position peaked at $2.65K in Q2 2026. 277 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Fairman Group reported no remaining Jazz Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Fairman Group sold 11 Jazz Pharmaceuticals shares in Q3 2026, an estimated $2.65K.
  • Fairman Group first reported a position in Jazz Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Fairman Group's Jazz Pharmaceuticals position peaked at $2.65K in Q2 2026.
  • 277 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Fairman Group's 13F filing for Q3 2026, filed 26 Oct 2026.